Details for Patent: 8,003,681

Which drugs does patent 8,003,681 protect, and when does it expire?

Patent 8,003,681 protects DUZALLO and ZURAMPIC and is included in two NDAs.

This patent has fifty-six patent family members in thirty-two countries.

Summary for Patent: 8,003,681

Title:	2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acet- ic acid and methyl ester
Abstract:	A series of S-triazolyl .alpha.-mercaptoacetanilides having general structure (1) are provided, where Q is CO.sub.2H, CONR.sub.2, SO.sub.3H, or SO.sub.2NR.sub.2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections. ##STR00001##
Inventor(s):	Girardet; Jean-Luc (San Diego, CA), Koh; Yung-Hyo (Irvine, CA)
Assignee:	Ardea Biosciences, Inc. (San Diego, CA)
Application Number:	12/633,638
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,003,681

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ironwood Pharms Inc	DUZALLO	allopurinol; lesinurad	TABLET;ORAL	209203-001	Aug 18, 2017		DISCN	Yes	No				Y
Ironwood Pharms Inc	DUZALLO	allopurinol; lesinurad	TABLET;ORAL	209203-002	Aug 18, 2017		DISCN	Yes	No				Y
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No				Y

International Family Members for US Patent 8,003,681

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	528001
Austria	540677
Australia	2005280130
Australia	2009217458
Brazil	PI0514630